Drug Trial Radar · NCT02349802
Autoinjector Device Assessment Study
Last checked: Nov 20, 2026Latest source record: Feb 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,052
Actual
Start
Feb 2013
Primary completion
Dec 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Celerion
- First posted
- Jan 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.
Conditions
- Healthy Subjects
Interventions
Auto-injector with exenatide suspensionDrug
A flexible study design to accommodate multiple cohorts.
Syringe with exenatide suspensionDrug
A flexible study design to accommodate multiple cohorts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of device-related failure injectionsTime frame: 10 week study
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Tempe, Arizona
Research Site
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.